Spiorad Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Spiorad Medical is a private, pre-revenue medical device startup targeting the vascular closure market, with a focus on large-bore access. Its core technology is a proprietary device intended to close large femoral arteriotomies created during procedures like transcatheter aortic valve implantation (TAVI) and complex endovascular aortic repair. The company is led by a CEO with commercial experience from major medtech firms and a Chief Medical Officer who is a practicing interventional cardiologist, providing strong clinical and market insight. Spiorad appears to be in the development and pre-clinical validation stage, supported by awards and collaborations within the Irish and European innovation ecosystem.

CardiovascularVascular

Technology Platform

Proprietary vascular closure device platform designed for large-bore (12F-24F) femoral artery access site closure, focusing on ease of use, reliability, and improved clinical outcomes.

Opportunities

The market for large-bore vascular closure is growing rapidly, driven by the expansion of TAVI and other complex transcatheter structural heart procedures.

There is a clear unmet need for a dedicated, easy-to-use device that can reduce complications and costs associated with current manual or off-label closure techniques.

Risk Factors

Key risks include technical failure in clinical testing, regulatory hurdles for a Class III device, and intense competition from both established medtech giants and new entrants.

As a pre-revenue startup, the company is also dependent on securing ongoing funding to reach commercialization.

Competitive Landscape

The competitive landscape includes large medtech companies like Abbott (Perclose ProGlide, often used off-label in a 'pre-close' technique) and a number of smaller private companies developing dedicated large-bore closure solutions. Competition is based on clinical efficacy, ease of use, and the ability to secure rapid physician adoption.

More companies in Drug Delivery & Formulation →More companies in Ireland →